Lyell Immunopharma, Inc. Weighted Average Number of Shares Outstanding, Diluted from 2019 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Lyell Immunopharma, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2019 to Q3 2025.
  • Lyell Immunopharma, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2025 was 18.3M shares, a 42.6% increase year-over-year.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 261M shares, a 4.18% increase from 2023.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 251M shares, a 1.58% increase from 2022.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 247M shares, a 81.8% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)

Lyell Immunopharma, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 18.3M +5.45M +42.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 14.8M +2.02M +15.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 295M +40.8M +16.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 261M +10.5M +4.18% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-11
Q3 2024 12.8M -239M -94.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 12.8M -237M -94.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 254M +4.66M +1.87% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 251M +3.9M +1.58% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-11
Q3 2023 251M +3M +1.21% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 250M +3.89M +1.58% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 250M +5.41M +2.22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 247M +111M +81.8% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-11
Q3 2022 248M +8.94M +3.73% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 246M +204M +477% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 244M +227M +1314% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 136M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 239M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 42.7M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 17.3M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10

Lyell Immunopharma, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 261M +10.5M +4.18% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-11
2023 251M +3.9M +1.58% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-11
2022 247M +111M +81.8% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-11
2021 136M +123M +925% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 13.3M +13.3M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 5.43K* Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.